Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Published:2022-05 Issue:5 Volume:9 Page:e309-e322
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Madhi Shabir A,Moodley Dhayendre,Hanley Sherika,Archary Moherndran,Hoosain Zaheer,Lalloo Umesh,Louw Cheryl,Fairlie Lee,Fouche Leon Frederik,Masilela Mduduzi S L,Singh Nishanta,Grobbelaar Coert,Ahmed Khatija,Benadé Gabriella,Bhikha Sutika,Bhorat As'ad Ebrahim,Bhorat Qasim,Joseph Natasha,Dheda Keertan,Esmail Aliasgar,Foulkes Sharne,Goga Ameena,Oommen Jose Aylin,Kruger Gertruida,Kalonji Dishiki J,Lalloo Natasha,Lombaard Johan J,Lombard Koen Anthonet,Kany Luabeya Angelique,Mngqibisa Rosie,Petrick Friedrich G,Pitsi Annah,Tameris Michele,Thombrayil Asha,Vollgraaff Pieter-Louis,Cloney-Clark Shane,Zhu Mingzhu,Bennett Chijioke,Albert Gary,Faust Emmanuel,Plested Joyce S,Fries Lou,Robertson Andreana,Neal Susan,Cho Iksung,Glenn Greg M,Shinde Vivek

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference24 articles.

2. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program;Nunes;PLoS One,2011

3. Risk factors for coronavirus disease (COVID-19) death in a population cohort study from the Western Cape Province, South Africa;Boulle;Clin Infect Dis,2021

4. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform;Bhaskaran;Lancet HIV,2021

5. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study;Jassat;Lancet HIV,2021

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials;Heliyon;2023-12

2. Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial;Wellcome Open Research;2023-11-27

3. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial;The Journal of Infectious Diseases;2023-11-16

4. The immune response to SARS-CoV-2 in people with HIV;Cellular & Molecular Immunology;2023-10-11

5. Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV;AIDS;2023-10-03